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rapid release of the drug whereas other modalities can have sustained 
drug delivery. The speakers in this forum will describe the pros and 
cons of each of the drug delivery systems that are designed to 
improve bioavailability of cancer chemotherapy to sites of neoplasia. 
X-ray guided drug delivery exploits the stress response within cancer 
that occurs during radiotherapy. Low doses of radiation induce DNA 
strand breaks and oxidative stress within cancer. Stress proteins such 
as GRP78, TIP1 and Calreticulin are induced and transported to the 
surface of cancer cells following irradiation. Antibodies and peptide 
ligands that are specific to these radiation inducible neoantigens are 
used to coat the surface of nanoparticles and liposomes for guided 
drug delivery. This strategy of x-ray guided drug delivery is analogous 
to military use of lasers to tag targets for smart bombs. X-rays are 
tissue penetrating and therefore tag deep seated cancers for the 
binding of antibodies and peptide ligands. The discovery platform for 
this technology identifies inducible antigens that are specific to 
cancer and not induced in normal tissues. Antigens that are induced in 
normal tissues are discarded while cancer specific antigens are 
developed. These targeting moieties are conjugated to drug delivery 
systems. In contrast, hyperthermia is used to heat a tumor. As 
liposomes pass through the tumors, the lipids melt and release the 
drug in that volume. This strategy of thermal regulation of drug 
delivery has entered Phase III clinical trials in breast cancer to deliver 
Doxorubicin. The use of magnetic nanoparticles for drug delivery is 
still in the preclinical stage. Paramagnetic nanoparticles have been 
targeted to tumors for both drug delivery and to heat tumors. 
Oscillating magnetic fields cause these nanoparticles to vibrate and 
heat the tumor to induce hyperthermia. These three forms of image 
guided drug delivery will becompared and contrasted during the 
debate of the practicality of bringing these new strategies of drug 
delivery into clinical trials.  
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Proton beam therapy seems to offer significant advantages over 
conventional techniques especially for the pediatric cohort and the 
number of children being treated with proton therapy for solid tumors 
is increasing rapidly throughout the world. There have been multiple 
dosimetric studies clearly demonstrating that protons decrease the 
irradiated volume and therefore the dose to the developing normal 
tissues compared with photon techniques while showing excellent 
outcome in the pediatric population. As in paediatric malignancies 
survival rates have increased considerably, from 0-20% until the 50ies 
up to about 80% today, quality of life (QoL) and late sequelae have 
become a major concern in pediatric cancer survivors. Therefore, 
proton therapy was understood as a tool potentially reducing the risk 
for secondary malignancy induction as well as for late effects. As 
children are particularly sensitive to radiation injury, they seem to be 
the cohort taking the greatest potential benefit from sparing dose to 
normal tissue. Today, local treatment with proton beam in CNS 
tumors or sarcomas is a common choice to be offered to the pediatric 
cohort in Europe and in US whenever available. 
It is suggested from early reports, that secondary cancer incidence 
may be reduced by 50% when using proton therapy. Additional early 
data was published on neurocognitive functioning and quality of life, 
both suggesting favourable outcome after proton beam therapy. Still, 
prospective data are limited, cohorts are small and observation times 
not sufficient, especially when looking at very young children being 
treated with proton beam therapy. 
In conclusion, proton beam therapy is a promising tool to explore 
particularly in the pediatric cohort to reduce the risk for late effects 
and secondary malignancies; however, due to limited availability up 
to now, clinical experience of proton therapy in childhood cancer is 
still limited. Therefore, all pediatric programs should be accompanied 
by prospective evaluations of late effects and QoL to gather more 
information on optimal use of proton therapy. Due to small number of 
patients and ethical considerations, randomized data will be hardly 
available even on the long term in children. Still, more clinical data 
will be emerging to quantify the clinical benefit of proton beam 
therapy with regard to a decrease in late effects while maintaining 
excellent cancer control rates.  
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Purpose/Objective: The aim of this study is to investigate the 
predictive value of the modelled tumour control probability (TCP) 
based on BED calculations using individual measurements of in vitro 
radiosensitivity (SF2) and potential doubling time (Tpot) for head and 
neck (H&N) cancer patients versus literature-based average 
radiobiological parameters. 
Materials and Methods: Tumour radiosensitivity, measured in vitro on 
primary biopsies and expressed as surviving fraction of cells following 
an acute exposure of 2 Gy (SF2), Tpot and tumour size were determined 
for 46 H&N cancer patients. All patients were treated with external 
beam radiotherapy and 28 patients also received brachytherapy. For 
each patient TCP was calculated using a Poisson-LQ model based 
either on the patient-specific radiobiological parameters or literature-
based average radiobiological parameters (α=0.3 Gy-1 and Tpot=3 days). 
The predicted TCP values for the two sets of parameters were 
compared with the actual outcome for the patients in terms of local 
control. 
Results: The average radiobiological parameters lead to a large 
underestimationof TCP as the predicted TCP was below 10% for the 
majority of the patients that actually presented local control. When 
tumour specific parameters were used,the majority of the patients 
with local control had a predicted TCP larger than 90%. 
A Receiver Operating Characteristic (ROC) curve analysis was also 
performed for assessing the predictive values of the two methods for 
calculating the TCP. The corresponding ROC curves are shown in 
Figure 1. 
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 Figure 1. ROC curves for TCP calculated using either average (dashed 
line) or patient specific (solid line) parameters α and Tpot. 
 
The dashed line corresponding to the TCP calculation based on 
average α and Tpot shows that the method has no power of 
discrimination with an area under the curve (AUC) of about 0.5. On 
the other hand, the ROC curve obtained based on patient specific α 
and Tpot (solid line) has an AUC of 0.7 and therefore this method does 
have an ability to distinguish between the two groups of patients 
presenting or not local control. The optimal threshold for TCP 
determined based on ROC analysis is 93% corresponding to a sensitivity 
of 66% and a specificity of 80%. 
Conclusions: This study shows that individual radiobiological 
parameters used for modelling TCP are better predictors of the 
radiation treatment outcome in individuals than literature-based 
average parameters.  
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Purpose/Objective: Residual microscopic disease (RMD) is considered 
to be the major cause of local recurrence in breast conserving 
therapy. Little knowledge, however, is available on how to optimally 
take the presence of RMD into consideration during radiotherapy. 
Traditionally, the whole breast is irradiated with/without a boost to 
the surgical bed. The purpose of this study was to optimize dose 
distributions to microscopic disease probability distribution obtained 
from detailed histopathology analyses. 
Materials and Methods: Population statistics of RMD were derived 
from 1818histopathology slides of 60 breast-cancer patients. The 
absolute quantity was fitted to a Poisson model and the relative ratio 
of RMD distribution was modeled with a half-Gaussian curve. A 
simulation framework was proposed. For simplicity,we assume a 
unifocal spherical tumor surgically removed from the center of a half 
spherical breast of 14 cm diameter with 5mm isotropic surgical 
margins.Perfectly spherical dose distributions with a 3.2 mm 
penumbra width were considered,while ignoring setup error and organ 
motion. A modified Webb-Nahum tumour control probability (TCP) 
model was adopted with parameters optimized to the histopathology 
data and the event data from the EORTC boost-vs-no-boost trial 
(uniform 50 Gy with/without 16 Gy at tumour bed) and the fifth cycle 
study of EBCTCG. Non-uniform dose distributions were optimized with 
TCPs equivalent to a uniform dose distribution of 50 Gy with and 
without a 16 Gy boost to a 3 cm diameter PTV. To that end, 10000 
virtual patients were sampled from the RMD probability distributions 
and the dose distributions were iteratively optimized by adding 1Gy at 
the radial distance with the largest TCP gain over the population of 
virtual patients. 
Results: The RMD volume per patient approximates 140 mm3on 
average and varies from 0 to 1076 mm3. One standard deviation(SD) of 
the half-Gaussian model was 6.3 mm (Figure 1-1, R-square 0.93). The 
radiosensitivity of disease cells in the TCP model is estimated to be 
0.056Gy-1 on average and with a Gaussian SD 0.009 Gy-1. The optimal 
dose distributions have a maximum dose 88 Gy at 1 mm to the surgical 
bed and the minimum dose 0 Gy (Figure 1-2). Our TCP model 
characteristics are shown by the relation curve between uniform dose 
and TCP assuming patients with average disease volume (Figure 2-1). 
The DVH within 25 mm to the surgical bed illustrates the possible 




Conclusions: Using a detailed microscopic disease distribution from 
histopathology analyses, the radiation treatment on the operated 
breast can be further optimized. The proposed dose distribution keeps 
the overall TCP the same but may largely reduce the high-radiation 
dose volume compared to the conventional treatment.  
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Purpose/Objective: Tumor hypoxia is associated with a poor outcome 
after radiotherapy. It can be assessed non-invasively by positron 
emission tomography (PET) using radiotracers that accumulate in 
poorly oxygenated tissue, such as 18F-Fluoromisonidazole (FMISO). 
However, only moderate correlations were reported between FMISO 
PET and direct PO2 measurements with oxygen sensing probes. 
Possible explanations were investigated in this study. Moreover, it was 
the purpose of this study to evaluate correlations between key figures 
of tumor oxygenation and different parameters that can be derived 
from FMISO PET imaging. 
Materials and Methods: Tumor tissue oxygenation was 
computationally simulated based on microvasculature images obtained 
from immunohistochemically stained tissue sections. Subsequently, 
the corresponding distribution-retention dynamics of FMISO was 
simulated. Sets of O2 and FMISO parameters were evaluated for 300 
distinct vessel configurations. As oxygenation key figures of a voxel, 
the vital hypoxic fraction (vHF) and the meanPO2 were chosen. For 
FMISO the PET voxel signal four hours after tracer injection (F4h) and 
the ratio between F4h and the mean signal during the first 15 min after 
injection (FH/P) were used. A correlation analysis was performed. This 
was followed by a receiver operating characteristic (ROC) analysis of 
how effectively hypoxia can be identified based on F4h and FH/P. 
Results: In hypoxic tissue F4h is well correlated with vHF (R2=0.90), 
while the correlation with meanPO2 is low (R2=0.22). A high nonlinear 
correlation was found between FH/P and meanPO2 (R2=0.99). The ROC 
analysis showed that tumor regions with a meanPO2 below 2.5 mmHg 
can be identified with high sensitivity and specificity by applying an 
appropriate threshold to FH/P (YI=sensitivity+specificity-1=0.94). The 
accuracy of F4h is considerably lower (YI=0.68). Both parameters are 
moderately effective in identifying critical PO2 levels on the 
microscopic length-scale (YI=0.63 and 0.60). 
Conclusions: A single static FMISO PET scan performed four hours 
after tracer injection appears to be suitable to estimate the vital 
hypoxic fraction in small tissue areas. A surrogate measure for the 
mean voxel PO2 might be provided by incorporating supplementary 
information from a second static FMISO PET scan performed instantly 
after tracer administration. Clinical investigations have to show which 
parameter is better suited for predicting radiotherapy outcome and, 
in a further step, might be used to prescribe a hypoxia-specific dose.  
   
